Advantage Investment Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Advantage Investment Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,500	Closed	-$6K	–	1008
2017 Q4	$6K	Hold	1,500	–	–	﹤0.01%	782
2017 Q3	$4K	Hold	1,500	–	–	﹤0.01%	845
2017 Q2	$4K	Hold	1,500	–	–	﹤0.01%	861
2017 Q1	$3K	Hold	1,500	–	–	﹤0.01%	858
2016 Q4	$2K	Hold	1,500	–	–	﹤0.01%	842
2016 Q3	$2K	Hold	1,500	–	–	﹤0.01%	819
2016 Q2	$1K	Hold	1,500	–	–	﹤0.01%	821
2016 Q1	$2K	Hold	1,500	–	–	﹤0.01%	765
2015 Q4	$4K	Hold	1,500	–	–	﹤0.01%	706
2015 Q3	$5K	Hold	1,500	–	–	﹤0.01%	652
2015 Q2	$6K	Hold	1,500	–	–	﹤0.01%	668
2015 Q1	$7K	Sell	1,500 -500	-25%	-$1.8K	﹤0.01%	644
2014 Q4	$6K	Buy	+2,000	New	+$5.49K	﹤0.01%	597

Other funds holding CPRX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Advantage Investment Management's CPRX Position: Q1 2018 in Review

Advantage Investment Management sold out of Catalyst Pharmaceutical (CPRX) in Q1 2018, closing a stake of 1,500 shares — an estimated $6K sold.

Advantage Investment Management first reported a position in CPRX in Q4 2014 and held it in 13 quarters. The position peaked at $7K in Q1 2015. 98 funds tracked by Wall St. Rank hold CPRX as of Q1 2018.

Advantage Investment Management reported no remaining Catalyst Pharmaceutical position as of Q1 2018 after selling out during the quarter.
Advantage Investment Management sold 1,500 Catalyst Pharmaceutical shares in Q1 2018, an estimated $6K.
Advantage Investment Management first reported a position in Catalyst Pharmaceutical in Q4 2014 and held it in 13 quarters.
Advantage Investment Management's Catalyst Pharmaceutical position peaked at $7K in Q1 2015.
98 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2018.

Based on Advantage Investment Management's 13F filing for Q1 2018, filed 15 May 2018.